1. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity
- Author
-
David Powers, Huilin Zhao, Li Zhu, Lilly Chai, Theodore Faust, Yan Gu, Yanyan Tudor, Anu Gore, Joseph L. Kim, Xiaotian Zhu, Antonio J. Oliveira-dos-Santos, Xin Huang, Monika Ermann, Susan M. Turci, Paul E. Rose, Debra Zack, Christina Boucher, Linda F. Epstein, Faye Hsieh, John Newcomb, Chiara Ghiron, Andrew A. Welcher, Sylvia Flores, Matthew W. Martin, Paul Gallant, Vinod F. Patel, Kurt Morgenstern, Scot Middleton, Carl-Gustaf Pierre Saluste, David N. Johnston, and Joseph J. Nunes
- Subjects
Male ,Models, Molecular ,Injections, Intradermal ,T-Lymphocytes ,Drug Evaluation, Preclinical ,Administration, Oral ,Pyrimidinones ,Pharmacology ,Crystallography, X-Ray ,Rats, Sprague-Dawley ,Mice ,Structure-Activity Relationship ,In vivo ,Drug Discovery ,Structure–activity relationship ,Transferase ,Animals ,Protein Kinase Inhibitors ,Mice, Inbred BALB C ,Tyrosine-protein kinase CSK ,biology ,Molecular Structure ,Chemistry ,Kinase ,Arthritis ,Anti-Inflammatory Agents, Non-Steroidal ,Reproducibility of Results ,Stereoisomerism ,Small molecule ,Rats ,Enzyme Activation ,Disease Models, Animal ,Biochemistry ,Enzyme inhibitor ,Lymphocyte Specific Protein Tyrosine Kinase p56(lck) ,Rats, Inbred Lew ,Drug Design ,biology.protein ,Molecular Medicine ,Interleukin-2 ,Benzimidazoles ,Female ,Signal transduction - Abstract
Lck, or lymphocyte specific kinase, is a cytoplasmic tyrosine kinase of the Src family expressed in T-cells and NK cells. Genetic evidence from knockout mice and human mutations demonstrates that Lck kinase activity is critical for T-cell receptor-mediated signaling, leading to normal T-cell development and activation. A small molecule inhibitor of Lck is expected to be useful in the treatment of T-cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection. In this paper, we describe the structure-guided design, synthesis, structure-activity relationships, and pharmacological characterization of 2-amino-6-phenylpyrimido[5',4':5,6]pyrimido[1,2- a]benzimidazol-5(6 H)-ones, a new class of compounds that are potent inhibitors of Lck. The most promising compound of this series, 6-(2,6-dimethylphenyl)-2-((4-(4-methyl-1-piperazinyl)phenyl)amino)pyrimido[5',4':5,6]pyrimido-[1,2- a]benzimidazol-5(6 H)-one ( 25), exhibits potent inhibition of Lck kinase activity. This activity translates into inhibition of in vitro cell-based assays and in vivo models of T-cell activation and arthritis, respectively.
- Published
- 2008